Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events Incidence of event · people following primary uncemented THA
It is very uncertain whether the intervention changes total adverse events Incidence of event (very low certainty).
1 finding from 1 review
Adverse events ‐ death · adults with common mental disorders
It is very uncertain whether primary‐level worker‐led collaborative care changes adverse events ‐ death compared with usual care (very low certainty).
1 finding from 1 review
Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with shallow NMB (very low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events Incidence of events · people following primary uncemented THA
1 finding from 1 review
Treatment cessation due to adverse events · CRRT
Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review
Adverse events (e.g. ulcers, tooth staining) · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events Adverse events per participant · people with spasticity following stroke
It is very uncertain whether systemic antispasticity drugs changes adverse events Adverse events per participant compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
1 finding from 1 review
Adverse events: readmission to clinical rehabilitation · people with spinal cord injury receiving rehabilitation treatment for the first time
It is very uncertain whether transmural care changes adverse events: readmission to clinical rehabilitation compared with usual follow‐up care (very low certainty).
1 finding from 1 review
Adverse events Self‐reported · patients with LBP
1 finding from 1 review
Adverse events Self‐reported · patients with LBP
1 finding from 1 review
Intervention not reported
Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Adverse events (not reported) · children with CP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular adverse events
Naftopidil showed no clear difference in cardiovascular adverse events compared with tamsulosin (alpha‐blocker) (low certainty).
1 finding from 1 review
Cardiovascular adverse events
Naftopidil showed no clear difference in cardiovascular adverse events compared with silodosin (alpha‐blocker) (low certainty).
1 finding from 1 review
Cardiovascular adverse events
Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).
1 finding from 1 review